Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.
MGMT
fotemustine
irradiation
recurrent glioblastoma
recurrent malignant glioma
second-line
surgery
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
05
03
2018
accepted:
26
07
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
Fotemustine (FTM) is a treatment option in recurrent malignant gliomas (MGs) after first-line Stupp treatment. The efficacy and the safety of fractionated FTM schedule proposed by Addeo
Identifiants
pubmed: 30655978
doi: 10.3892/mco.2018.1746
pii: MCO-0-0-1746
pmc: PMC6313958
doi:
Types de publication
Journal Article
Langues
eng
Pagination
58-66Références
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Eur J Cancer. 1991;27(7):852-6
pubmed: 1834116
J Clin Oncol. 2008 May 1;26(13):2192-7
pubmed: 18445844
Cancer. 2008 Jul 15;113(2):405-10
pubmed: 18484594
Anticancer Drugs. 2008 Jul;19(6):613-20
pubmed: 18525321
J Neurooncol. 2009 Mar;92(1):79-86
pubmed: 19018476
Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75
pubmed: 19169684
BMC Cancer. 2009 Mar 31;9:101
pubmed: 19335893
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Neurooncol. 2010 Nov;100(2):209-15
pubmed: 20352471
J Neurooncol. 2011 May;102(3):417-24
pubmed: 20694830
Cancer Chemother Pharmacol. 2011 May;67(5):971-83
pubmed: 21442438
Neurol Sci. 2011 Nov;32 Suppl 2:S255-7
pubmed: 21987288
J Transl Med. 2012 May 14;10:90
pubmed: 22583678
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223
J Neurooncol. 2013 Jul;113(3):527-9
pubmed: 23703296
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
Cancers (Basel). 2012 Feb 01;4(1):77-87
pubmed: 24213227
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
Biomed Res Int. 2014;2014:698542
pubmed: 24800248
Lancet Oncol. 2014 Aug;15(9):943-53
pubmed: 25035291
Clin Cancer Res. 2015 May 1;21(9):2057-64
pubmed: 25655102
Clin Neurol Neurosurg. 2016 Mar;142:60-64
pubmed: 26811867
Crit Rev Oncol Hematol. 2016 Mar;99:389-408
pubmed: 26830009
Neuro Oncol. 2016 Sep;18(9):1304-12
pubmed: 26951379
Curr Treat Options Oncol. 2016 Sep;17(9):49
pubmed: 27461038
J Clin Oncol. 2017 Jan 20;35(3):361-369
pubmed: 27893327
J Neurooncol. 2017 May;132(3):419-426
pubmed: 28374095